高危腹部大手术患者使用羟乙基淀粉与生理盐水进行容量替代治疗对死亡或术后并发症的影响:FLASH随机临床试验
FLASH为多中心、双盲、平行组随机临床试验,纳入法国20所大学医院中接受腹部大手术且术后肾损伤风险增加的成人患者775例。患者随机接受6%羟乙基淀粉130/0.4溶于0.9%生理盐水(n=389)或单用0.9%生理盐水(n=386),以250 mLboluses按个体化血流动力学算法术中及术后第1天至次日上午7:59给药。主要终点14天内死亡或主要术后并发症复合终点在HES组139/389例(36%)vs生理盐水组125/386例(32%),差异3.3%(95%CI -3.3%至10.0%),RR 1.10(95%CI 0.91-1.34),P=0.33。12项预设次要终点中11项无显著差异,但第1天研究液体中位用量HES组1250 mL(IQR 750-2000 mL)vs生理盐水组1500 mL(IQR 750-2150 mL),中位差250 mL(95%CI 83-417 mL),P=0.006;术后28天死亡率HES组4.1% vs生理盐水组2.3%,差异1.8%(95%CI -0.7%至4.3%),RR 1.76(95%CI 0.79-3.94),P=0.17。作者结论认为这些发现不支持在此类患者中使用HES进行容量替代治疗。
要点
- 高危腹部大手术患者术中及术后第1天使用6%HES 130/0.4与0.9%生理盐水相比,14天内死亡或主要术后并发症复合终点36% vs 32%,差异3.3%(95%CI -3.3%至10.0%),RR 1.10(95%CI 0.91-1.34),P=0.33,无显著差异。
- 12项预设次要终点中11项无显著差异;第1天研究液体中位用量HES组1250 mL vs生理盐水组1500 mL,中位差250 mL(95%CI 83-417 mL),P=0.006。
- 术后28天全因死亡率HES组4.1% vs生理盐水组2.3%,差异1.8%(95%CI -0.7%至4.3%),RR 1.76(95%CI 0.79-3.94),P=0.17,未达统计学显著。
- 作者结论:在这些术后肾损伤风险增加的腹部大手术患者中,HES与0.9%生理盐水相比主要复合终点无显著差异,这些发现不支持使用HES进行容量替代治疗。
适用人群与场景
- 接受腹部大手术且术后肾损伤风险增加的成人患者;纳入826例,平均年龄68岁(SD 7),女性91例(12%),775例(94%)完成试验。
- 研究在法国20所大学医院进行,时间为2016年2月至2018年7月,最终随访于2018年10月。
处置流程与药物剂量
- 患者随机接受6%羟乙基淀粉130/0.4溶于0.9%生理盐水(n=389)或单用0.9%生理盐水(n=386),以250 mLboluses给药,采用个体化血流动力学算法,于术中及术后第1天至次日上午7:59使用。
研究设计与关键结果
- 多中心、双盲、平行组随机临床试验,纳入775例接受腹部大手术且术后肾损伤风险增加的成人患者,比较6%HES 130/0.4与0.9%生理盐水容量替代治疗。
- 主要终点(14天内死亡或主要术后并发症复合终点):HES组139/389例(36%)vs生理盐水组125/386例(32%),差异3.3%(95%CI -3.3%至10.0%),RR 1.10(95%CI 0.91-1.34),P=0.33。
- 12项预设次要终点中11项无显著差异;第1天研究液体中位用量HES组1250 mL(IQR 750-2000 mL)vs生理盐水组1500 mL(IQR 750-2150 mL),中位差250 mL(95%CI 83-417 mL),P=0.006。
- 术后28天全因死亡率:HES组4.1% vs生理盐水组2.3%,差异1.8%(95%CI -0.7%至4.3%),RR 1.76(95%CI 0.79-3.94),P=0.17。
证据类型、等级与局限
- 证据类型:多中心、双盲、平行组随机临床试验(FLASH试验),ClinicalTrials.gov注册号NCT02502773。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者结论认为,在这些术后肾损伤风险增加的腹部大手术患者中,使用HES进行容量替代治疗与0.9%生理盐水相比主要复合终点无显著差异,这些发现不支持使用HES进行容量替代治疗。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: It is not known if use of colloid solutions containing hydroxyethyl starch (HES) to correct for intravascular deficits in high-risk surgical patients is either effective or safe.
OBJECTIVE: To evaluate the effect of HES 130/0.4 compared with 0.9% saline for intravascular volume expansion on mortality and postoperative complications after major abdominal surgery.
DESIGN, SETTING, AND PARTICIPANTS: Multicenter, double-blind, parallel-group, randomized clinical trial of 775 adult patients at increased risk of postoperative kidney injury undergoing major abdominal surgery at 20 university hospitals in France from February 2016 to July 2018; final follow-up was in October 2018.
INTERVENTIONS: Patients were randomized to receive fluid containing either 6% HES 130/0.4 diluted in 0.9% saline (n = 389) or 0.9% saline alone (n = 386) in 250-mL boluses using an individualized hemodynamic algorithm during surgery and for up to 24 hours on the first postoperative day, defined as ending at 7:59 am the following day.
MAIN OUTCOMES AND MEASURES: The primary outcome was a composite of death or major postoperative complications at 14 days after surgery. Secondary outcomes included predefined postoperative complications within 14 days after surgery, durations of intensive care unit and hospital stays, and all-cause mortality at postoperative days 28 and 90.
RESULTS: Among 826 patients enrolled (mean age, 68 [SD, 7] years; 91 women [12%]), 775 (94%) completed the trial. The primary outcome occurred in 139 of 389 patients (36%) in the HES group and 125 of 386 patients (32%) in the saline group (difference, 3.3% [95% CI, -3.3% to 10.0%]; relative risk, 1.10 [95% CI, 0.91-1.34]; P = .33). Among 12 prespecified secondary outcomes reported, 11 showed no significant difference, but a statistically significant difference was found in median volume of study fluid administered on day 1: 1250 mL (interquartile range, 750-2000 mL) in the HES group and 1500 mL (interquartile range, 750-2150 mL) in the saline group (median difference, 250 mL [95% CI, 83-417 mL]; P = .006). At 28 days after surgery, 4.1% and 2.3% of patients had died in the HES and saline groups, respectively (difference, 1.8% [95% CI, -0.7% to 4.3%]; relative risk, 1.76 [95% CI, 0.79-3.94]; P = .17).
CONCLUSIONS AND RELEVANCE: Among patients at risk of postoperative kidney injury undergoing major abdominal surgery, use of HES for volume replacement therapy compared with 0.9% saline resulted in no significant difference in a composite outcome of death or major postoperative complications within 14 days after surgery. These findings do not support the use of HES for volume replacement therapy in such patients.
TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02502773.
参考来源
- Futier E, Garot M, Godet T, et al. Effect of Hydroxyethyl Starch vs Saline for Volume Replacement Therapy on Death or Postoperative Complications Among High-Risk Patients Undergoing Major Abdominal Surgery: The FLASH Randomized Clinical Trial. JAMA. 2020. PMID: 31961418. doi:10.1001/jama.2019.20833
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。